ZENECA ZOLADEX SALES UP 34% TO $195 MIL. IN FIRST HALF; ZESTRIL VOLUME GROWS 14%, REVENUES RISE 10% TO $379 MIL.: U.S. PHARMA CERVICAL SALES TOTAL $623 MIL.
Executive Summary
Zeneca's Zoladex sales climbed 34% to $195 mil. for the first half of 1995 with a sales volume increase of 33%, a price decrease of 2% and a 2% loss due to currency exchange fluctuations, the company reported at an Aug. 3 meeting with securities analysts in New York City